These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30239876)

  • 21. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA
    Jia N; Jones R; Yang G; Ouerfelli O; Patel DJ
    Mol Cell; 2019 Sep; 75(5):944-956.e6. PubMed ID: 31326273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of cyclic tetra-oligoadenylate processing by small standalone CRISPR-Cas ring nucleases.
    Molina R; Garcia-Martin R; López-Méndez B; Jensen ALG; Ciges-Tomas JR; Marchena-Hurtado J; Stella S; Montoya G
    Nucleic Acids Res; 2022 Oct; 50(19):11199-11213. PubMed ID: 36271789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease.
    Sheppard NF; Glover CV; Terns RM; Terns MP
    RNA; 2016 Feb; 22(2):216-24. PubMed ID: 26647461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of Target RNA Cleavage of a III-B CRISPR-Cas System Induces Robust Autoimmunity in
    Zhang Y; Lin J; Tian X; Wang Y; Zhao R; Wu C; Wang X; Zhao P; Bi X; Yu Z; Han W; Peng N; Liang YX; She Q
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. If You'd Like to Stop a Type III CRISPR Ribonuclease, Then You Should Put a Ring (Nuclease) on It.
    Mo CY; Marraffini LA
    Mol Cell; 2018 Nov; 72(4):608-609. PubMed ID: 30444997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
    Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
    Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.
    Pan S; Li Q; Deng L; Jiang S; Jin X; Peng N; Liang Y; She Q; Li Y
    RNA Biol; 2019 Sep; 16(9):1166-1178. PubMed ID: 31096876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator.
    Athukoralage JS; Graham S; Grüschow S; Rouillon C; White MF
    J Mol Biol; 2019 Jul; 431(15):2894-2899. PubMed ID: 31071326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural insight into the Csx1-Crn2 fusion self-limiting ribonuclease of type III CRISPR system.
    Zhang D; Du L; Gao H; Yuan C; Lin Z
    Nucleic Acids Res; 2024 Aug; 52(14):8419-8430. PubMed ID: 38967023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A type III-B CRISPR-Cas effector complex mediating massive target DNA destruction.
    Han W; Li Y; Deng L; Feng M; Peng W; Hallstrøm S; Zhang J; Peng N; Liang YX; White MF; She Q
    Nucleic Acids Res; 2017 Feb; 45(4):1983-1993. PubMed ID: 27986854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis for cA6 synthesis by a type III-A CRISPR-Cas enzyme and its conversion to cA4 production.
    Goswami HN; Ahmadizadeh F; Wang B; Addo-Yobo D; Zhao Y; Whittington AC; He H; Terns MP; Li H
    Nucleic Acids Res; 2024 Sep; 52(17):10619-10629. PubMed ID: 38989619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of cyclic oligoadenylate binding to the transcription factor Csa3 outlines cross talk between type III and type I CRISPR systems.
    Xia P; Dutta A; Gupta K; Batish M; Parashar V
    J Biol Chem; 2022 Feb; 298(2):101591. PubMed ID: 35038453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
    Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
    Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral type III CRISPR signalling via conjugation of ATP and SAM.
    Chi H; Hoikkala V; Grüschow S; Graham S; Shirran S; White MF
    Nature; 2023 Oct; 622(7984):826-833. PubMed ID: 37853119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of cyclic oligoadenylate synthesis in a type III CRISPR system.
    Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
    Elife; 2018 Jul; 7():. PubMed ID: 29963983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic properties of CARF-domain proteins in
    Ding J; Schuergers N; Baehre H; Wilde A
    Front Microbiol; 2022; 13():1046388. PubMed ID: 36419420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of III-B CRISPR-Cas systems in archaea.
    Zhang Y; Lin J; Feng M; She Q
    Emerg Top Life Sci; 2018 Dec; 2(4):483-491. PubMed ID: 33525825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Csm6 ribonuclease by cyclic nucleotide binding: in an emergency, twist to open.
    McQuarrie S; Athukoralage JS; McMahon SA; Graham S; Ackermann K; Bode BE; White MF; Gloster TM
    Nucleic Acids Res; 2023 Oct; 51(19):10590-10605. PubMed ID: 37747760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cmr4 is the slicer in the RNA-targeting Cmr CRISPR complex.
    Zhu X; Ye K
    Nucleic Acids Res; 2015 Jan; 43(2):1257-67. PubMed ID: 25541196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.